Stay updated with breaking news from Michael Castagna. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MannKind Co. (NASDAQ:MNKD – Get Free Report) shares rose 10.6% during trading on Wednesday . The company traded as high as $4.26 and last traded at $4.18. Approximately 1,060,401 shares traded hands during trading, a decline of 56% from the average daily volume of 2,431,067 shares. The stock had previously closed at $3.78. Wall Street […]
2023 Total revenues of $199M; +99% vs. 20224Q 2023 Total revenues of $58M; +62% vs. 20224Q 2023 Net income of $1M; Non-GAAP net income of $7M$302M of cash and cash equivalents and investments at...
C M Bidwell & Associates Ltd. bought a new position in shares of MannKind Co. (NASDAQ:MNKD – Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 25,685 shares of the biopharmaceutical company’s stock, valued at approximately $106,000. A […]
C M Bidwell & Associates Ltd. bought a new position in shares of MannKind Co. (NASDAQ:MNKD – Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The fund bought 25,685 shares of the biopharmaceutical company’s stock, valued at approximately $106,000. Other institutional investors have also modified […]
MannKind CEO Michael Castagna (file photo) Westlake Village-based MannKind Corporation saw shares climb 8% on Jan. 2 after the company announced entering into a royalty purchase agreement of up to $200 million. MannKind, a biotechnology company that develops treatments for diabetes and pulmonary arterial hypertension, sold a 1% royalty in net sales of Tyvaso DPI